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Perfluoro-n-octane as a temporary intraocular 
tamponade in a staged approach to manage 
complex retinal detachments
Daniel Barthelmes
Jay Chandra
Department of Ophthalmology, 
Westmead hospital, Westmead, 
nsW, australia
Purpose: To evaluate outcomes in patients with complex retinal detachments (RD) with 
proliferative vitreoretinopathy (PVR) requiring retinectomy using a staged approach utilizing 
perfluoro-n-octane (PFO) as a short-term postoperative intraocular tamponade.
Methods: Retrospective analysis. Patients who underwent 23G pars plana vitrectomy for 
the management of complicated RD where PFO was used as a primary temporary intraocular 
tamponade. Only eyes with PVR in rhegmatogenous RD or eyes with penetrating injuries or 
globe ruptures (ocular trauma) and subsequent RD with PVR were included. Analysis of 17 eyes 
of 17 consecutive patients with a minimum follow-up of 12 months during a period of 5 years. 
The primary outcome measure was the reattachment rate after at least 12 months of follow-up 
after the PFO removal. Secondary outcome measures were changes in visual acuity, complica-
tions due to PFO use, and necessity for further surgeries.
Results: Eight eyes with prior penetrating injuries or globe rupture and nine eyes with rheg-
matogenous pathology were included. All eyes had PFO as temporary tamponade for 14 days 
(median), which was replaced by silicon oil. Sixteen eyes (94%) had complete and one eye 
partial reattachment. No redetachments occurred. All eyes retained or improved visual acuity. 
On average, only 2.5 procedures, including silicon oil removal, were performed. Two eyes had 
long-term intraocular pressure of 5 mmHg and no eye had intraocular pressure of 21 mmHg. 
No long-term inflammation was observed.
Conclusion: PFO seems to be beneficial in a staged approach to repair complex detachments 
when used as short-term tamponade. A median period of 14 days allowed for both sufficient 
retinal support plus a reduction in side effects seen in long-term endotamponades.
Keywords: pars plana vitrectomy, complex retinal detachments, proliferative vitreoretinopathy, 
trauma
Introduction
One of the big challenges in vitreoretinal surgery is management of complex retinal 
detachments (RD) following trauma or RD with extensive proliferative vitreoretin-
opathy (PVR). PVR has been reported to occur in up to 11% of patients with rheg-
matogenous RD1 or in the course of penetrating eye injuries and globe ruptures at an 
estimated incidence of 10%–45%.2 A recent report on injured soldiers showed even 
up to 70% PVR.3
The traction caused by retinal shortening occurs preferably in the inferior quadrant 
near or in the vitreous base.4–7 Management of complex RD includes scleral buckling, 
pars plana vitrectomy (PPV), retinectomy, removal of proliferative membranes, and the 
use of perfluorocarbon liquids or silicon oil. Since standard silicon oil provides inap-
propriate support for inferior retinal pathologies, “heavier than water” endotamponades 
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were developed.8 These substances were reported to be not 
suitable for long-term tamponades, such being necessary in 
cases of PVR.9,10 Later, perfluorohexyloctanes also showed 
complications as a long-term vitreous substitute.11–13 Main 
problems were intraocular inflammation and toxicity.11,14 The 
currently available “heavy” silicon oils such as Densiron 68® 
seem to be better tolerated but have also been reported 
to show side effects such as intraocular inflammation.15,16 
A number of recent studies reported on the possibility of 
using perfluoro-n-octane (PFO) as a short-term endotam-
ponade that is replaced by air, C3F8, or silicon oil after 
a period of 1–2 weeks.17,18 So far, the results achieved in giant 
retinal tears seem to be promising: ie, retinal attachment was 
achieved with minimal side effects of PFO.17,18
The current study describes the use of PFO as a short-term 
tamponade in a staged approach to manage cases of complex 
PVR-related RD in eyes with rhegmatogenous RD and eyes 
suffering from ocular trauma.
Methods
Patients
Retrospective analysis of all patients who underwent 23G 
PPV at the Department of Ophthalmology, Westmead 
Hospital, Westmead, NSW, Australia, for the management 
of complicated RD where PFO (Perfluoron®, Alcon Labo-
ratories, Inc., Fort Worth, TX, USA) was used as a primary 
temporary intraocular tamponade. Observation period was 
from August 1, 2006 to December 31, 2011. Only eyes were 
included with no prior vitreoretinal surgery showing PVR in 
rhegmatogenous detachments or RD with PVR in eyes with 
penetrating injuries or globe ruptures (ocular trauma). Eyes 
with other reasons for traction membranes were excluded, 
as well as eyes with redetachments after previous retinal 
detachment repairs. A detailed description of routine care 
for patients undergoing 23G PPV at the same hospital was 
published previously.19
The decision to use PFO as a primary short-term endot-
amponade was made in cases where after successful intra-
operative flattening of the retina, no stable situation could 
be achieved when gas or silicon oil was used: ie, in cases 
of a high risk of immediate redetachment. A high risk of 
immediate redetachment was considered in situations where 
large retinectomies had to be performed and posterior retinal 
slippage would occur once PFO was removed, extensive 
inferior pathology or an impossibility to completely remove 
all traction membranes where the retinal tissue would remain 
completely attached only under PFO.
surgical technique
All eyes included in this study underwent a standard 
three-port PPV using the Alcon 23G system (Accurus® 
800CS). The surgical technique for 23G PPV was described 
previously.19 Briefly, a complete vitrectomy was performed 
with scleral depression to improve visualization of the 
vitreous base and to assist the meticulous removal of the 
vitreous. If possible, traction membranes were completely 
removed. In cases where it was not possible to remove the 
whole traction membrane, a retinectomy was performed 
to release traction using the 23G vitrector after applying 
full-thickness retinal cautery. All retinal tissue anterior to 
the retinectomy was removed. If a buckle was in place, all 
retinal tissue anterior to the retinectomy, up to the apex of 
the buckle, or up to the edge where the retina was firmly 
attached to the buckle, was removed. The retina was then 
flattened using PFO. The posterior edges of the retinectomy 
were treated using an endolaser probe (Oculas, Alcon, Forth 
Worth, TX, US), with at least three to four rows of laser 
spots. After successful reattachment of the retina, the eye 
was completely filled with PFO, and all sclerotomy ports 
sutured with 7-0 vicryl sutures.
In phakic patients, the crystalline lens was removed 
before starting the vitrectomy, and in case of an intact capsule 
an intraocular lens was implanted (Alcon MA50BM): ie, 
eyes were either aphakic (eg, trauma cases) or pseudophakic 
before starting the retinal repair. Chandelier systems were 
used if deemed necessary to facilitate bimanual dissection 
of retinal membranes or retinal tissue. In cases of extensive 
lacerations of the globe or extensive inferior PVR, an encir-
cling buckle was put in place in the same surgical session 
prior to starting the 23G PPV.
Approximately 2 weeks after the first vitreoretinal sur-
gery, a second 23G PPV was performed where PFO was 
completely evacuated from the vitreous cavity and replaced 
by silicon oil (Oxane 1300, Bausch and Lomb, Macquarie 
Park, NSW, Australia). All ports were sutured using 7-0 
vicryl sutures.
Depending on the initial pathology, the status of the 
retina, and the patient’s visual potential, a third 23G PPV 
was performed to remove the silicon oil from the vitreous 
cavity approximately 3–4 months after the silicon oil filling. 
In these cases, the eye was filled with 25% SF6 gas to prevent 
postoperative hypotony. Generally, in cases with low visual 
potential (eg, macular retinal damage) and an estimated 
high risk of hypotony, the silicon oil was left as permanent 
endotamponade.
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Data
Data were retrieved from the patients’ records. The infor-
mation collected included sex; preoperative best-corrected 
visual acuity (VA, LogMAR [log of the minimum angle of 
resolution]) before the initial PPV; age; dates of surgeries 
performed; types of surgeries performed, including buckle 
surgery; lens status before vitrectomy; and initial pathology/
reason for vitreoretinal repair. Postoperative data analyzed 
were best-corrected VA during the follow-up phase; final 
retinal status; final presence of silicon oil endotamponade; 
complications such as retinal redetachment, corneal opacifi-
cation, and endophthalmitis; and significant intraocular pres-
sure (IOP) changes. VA was recorded using a Snellen scale 
and converted to the LogMAR scale. Institutional Review 
Board/Ethics Committee approval was obtained from the 
local Ethics Committee at the Westmead Hospital. The study 
adheres to the tenets of the Declaration of Helsinki.
statistical analysis
Statistical analyses were performed using PASW 19 (SPSS 
Inc., Chicago, IL, USA). Normally distributed data are pre-
sented as mean ± standard deviation; not normally distrib-
uted data are presented as median and range (minimum to 
maximum). Data distribution was assessed using the Shapiro–
Wilk and Kolmogorov–Smirnov tests. Differences in vari-
ances were assessed using Levene’s test. Depending on data 
distribution, tests for not normally or normally distributed 
data were used taking into account possible pairing of sam-
ples and inequality of variances. Differences in proportions 
were assessed using Fisher’s exact test. Results are expressed 
as odds ratio and 95% confidence interval. IOP was classi-
fied as increased if 21 mmHg with or without glaucoma 
medication. Hypotony was classified as IOP 5 mmHg.20,21 
Corneal haze was graded as “present” or “not present”. 
Statistical significance was defined as P0.05.
Results
After applying inclusion and exclusion criteria, 17 eyes from 
17 patients were available for final analysis from the observa-
tion period August 1, 2006 to December 31, 2011 (~5.3 years). 
In all 17 eyes, complete documentation and follow-up data 
were available. Follow-up time was 37.1±20.1 (range 12–64) 
months. The exact time at which retinal detachment developed 
could not be determined in most cases, due to patient logis-
tics: ie, referral patterns and primary care in case of trauma. 
Eyes with trauma are treated immediately by the surgeon on 
call, not by the vitreoretinal unit. In most cases, vitreoretinal 
surgery was performed often 7–10 days after primary repair. 
In patients with rhegmatogenous detachments, symptoms 
have been reported to be present for at least 2–3 months.
The 17 eyes were from 12 (71%) men and five (29%) 
women. Mean age at the time of the first surgical interven-
tion was 44.2±16.2 years (men 46.1±16.4, women 39.8±16.4, 
P=0.48). A strong imbalance regarding the side affected was 
found: two (12%) right eyes and 15 (88%) left eyes were 
observed. Patients in the group with rhegmatogenous detach-
ments were older (51.3±5.1 years) as compared with patients 
with traumatized eyes (36.3±4.9 years); the difference was 
not significant (P=0.051).
Eight eyes (47%) had previous traumatic damage and 
subsequent development of a retinal detachment with PVR, 
while nine eyes (53%) had rhegmatogenous detachments 
and severe PVR (grade C or D) development. Seven eyes 
(41%) were aphakic at the first PPV; all of them had suffered 
from ocular trauma (globe rupture, penetrating eye injury) 
that effectuated loss of intraocular tissue, including the crys-
talline lens. Only one of the eight eyes with trauma could 
retain the crystalline lens. This was removed with a standard 
phacoemulsification procedure before the 23G PPV. No eye 
with rhegmatogenous RD was aphakic. The preoperative (ie, 
before the first 23G PPV) VA in all patients was 3.0 (0.8–4.0) 
LogMAR, whereas preoperative VA in traumatized eyes was 
4.0 (2.0–4.0) LogMAR and in eyes with rhegmatogenous 
detachments was 3.0 (0.8–4.0) LogMAR (P=0.34). Table 1 
gives a detailed overview.
All eyes had anterior retinal defects of at least 2 clock 
hours either due to traumatic damage or due to necessary 
retinectomies. An encircling buckle was placed in eleven 
eyes (65%), where four of the eight eyes with traumatic 
damage and seven of the nine eyes with rhegmatogenous 
retinal detachment had buckle surgery. The difference in 
proportions in buckle surgery between both groups was not 
significant (P=0.33).
The time between the PFO filling (first 23G PPV) and 
the PFO removal/silicon oil filling (second 23G PPV) was 
14 (13–28) days.
Complete reattachment of the retina was achieved in 16 
of 17 eyes (94%). In one eye of the group of eyes having suf-
fered from penetrating injury, new subretinal traction bands 
developed under the silicon oil tamponade, which led to a 
small redetached area in the inferior fundus. As the macular 
region and the remaining retina were stabilized, no further 
interventions were planned and the situation remained stable: 
ie, no further deterioration or detachment occurred.
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In case the silicon oil was left as a permanent endotam-
ponade, only two 23G PPVs were performed (PFO filling/
PFO removal and silicon oil filling); all other eyes had an 
additional surgery in which the silicon oil was exchanged for 
SF6. The median number of 23G PPVs in all eyes was two. 
No significant difference was found between traumatized 
eyes and eyes with rhegmatogenous detachments. In eyes 
with rhegmatogenous detachments, in only three of nine 
(33%) could the silicon oil be removed, while in the eyes 
with previous trauma, in five of eight (63%) the silicon oil 
could be removed (P=0.35). Postoperative VA in all eyes 
was 1.0 (0.5–4.0) LogMAR, which is a significant increase 
compared with preoperative VA (P=0.0016). Postoperative 
VA in eyes with previous rhegmatogenous detachments was 
1.0 (0.5–3.0) LogMAR and 1.2 (0.8–4.0) LogMAR in eyes 
with previous trauma. In both rhegmatogenous detachments 
(P=0.031) as well as in eyes with previous trauma (P=0.021), 
VA significantly increased and no differences in postopera-
tive VA were found between both groups (P=0.52). All eyes 
either retained or improved VA. There was no difference 
in the proportion of eyes achieving 1 LogMAR or better 
between eyes with rhegmatogenous detachments versus 
those with previous trauma. The best visual recoveries 
(0.6 LogMAR or better) were achieved in eyes with previous 
rhegmatogenous detachments only.
None of the eyes developed glaucoma. Two eyes were 
hypotonic (Table 1). All eyes were stable, no redetachments 
occurred, and in none of the eyes was further surgery or laser 
photocoagulation required. Three eyes (all three eyes initially 
had globe ruptures with loss of intraocular tissue and loss 
of the crystalline lens) developed a hazy cornea during the 
follow-up period; none of these eyes had a permanent endot-
amponade with silicon oil. During the PFO endotamponade 
period, anterior chamber inflammation could be observed 
in all eyes. This subsided after the PFO removal and, even-
tually, no eye had persistent intraocular inflammation. As 
a consequence of the anterior chamber inflammation, five 
eyes developed posterior synechiae. No endophthalmitis 
was observed.
Discussion
To our knowledge, this is the first report on PFO as a primary 
short-term endotamponade in a staged approach to manage 
complex retinal detachment in eyes with extensive retinal 
damage that did not undergo any previous vitreoretinal repair. 
Complete retinal attachment was achieved in 94% of eyes, at 
an overall average of only 2.5 23G PPV per eye, including 
the final silicon oil removal.T
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Overall, the results of the current study in respect of 
reattachment rate (complete reattachment in 94%) and sili-
con oil removal rate (47%) are comparable with previous 
results in a similar patient cohort with inferior pathology, 
PVR, and inferior retinectomy.22 The number of additional 
surgeries after the retinectomy was reported to be, on aver-
age, 1.8 including the silicon oil removal, which is slightly 
higher compared with the currently reported 1.5 surgeries 
including the silicon oil removal. In contrast to reports 
analyzing PFO in complex detachments where most of the 
eyes had already undergone one or more surgeries to reat-
tach the retina,17,22 none of the eyes in this study had previ-
ous vitreoretinal surgery. Given this, using the described 
approach, the number of surgeries in complex RD with 
PVR can be reduced significantly: the primary repair using 
PFO, the removal of PFO and replacement with silicon oil, 
and possibly the removal of silicon oil and replacement by 
gas. Furthermore, using the proposed approach and avoid-
ing extensive retinectomy and aggressive relief of traction 
membranes – which are factors that may lead to further PVR 
development and potential final surgical failure – may have 
contributed to the results reported. Especially in younger 
patients, such as those with severe injuries and a higher 
potential for PVR and risk of retinal redetachment under 
silicone oil, primary use of PFO may be an alternative to 
achieve stable reattachment.
When using PFO for a short time only (in the current 
study 14 days [median]), similarly to reports in giant retinal 
tears,18,23 the clear benefits of a sufficient retinal support 
were combined with a reduction of side effects, as PFO is 
completely removed after 1–2 weeks. Nevertheless, some of 
the side effects, such as inflammation or corneal opacifica-
tion, cannot be completely avoided. Despite corticosteroid 
medication, some degree of intraocular inflammation could 
be observed in all eyes during the PFO endotamponade, 
which may have contributed to the formation of posterior 
synechiae observed in five eyes. Corneal opacification that 
occurred in aphakic eyes with previous trauma may be an 
argument against the usage of PFO as a primary endotampon-
ade. However, as the retina could be reattached in all these 
eyes and remained stable, it may be possible to perform a 
keratoplasty later. It may be argued that corneal endothelial 
damage should be avoided, especially in aphakic or aniridic 
eyes, since corneal surgery adds additional trauma, and out-
comes of corneal transplant procedures are less favorable. 
However, given the retinal damage, a high risk for final 
surgical failure and eventual loss of the eye when using gas 
or silicone oil initially has to be balanced against sequelae 
of using PFO while still retaining good potential for visual 
recovery after keratoplasty.
While 14 eyes had a normal IOP, two eyes developed 
hypotony. These two eyes had penetrating injuries and globe 
ruptures with loss of the crystalline lens and iris tissue. It 
is not clear whether the hypotony is the effect of the PFO 
tamponade24 or rather an effect of the damage inflicted to the 
anterior segment of the eye, including the ciliary body. One 
could argue that heavy silicon oil may be an alternative to 
PFO fillings. However, also for Densiron 68®, for example, 
side effects such as inflammation and mechanical damage 
were reported.15,16 Another important factor is that the han-
dling of heavy silicon oils is more difficult and takes more 
time as compared with PFO, especially when using small 
gauge instruments. While it has been reported that Densiron 
endotamponades can be managed with 23G instruments, 
though using very high suction pressures of 600 mmHg,25 
the ability to inject and remove PFO using a plain syringe 
with soft-tip cannulas appears more appealing in complex 
cases such as those described here.
The use of buckling surgery especially in aphakic or 
pseudophakic eyes may warrant brief discussion. Especially 
in traumatized eyes, adding an encircling buckle may add 
to orbital trauma and to long-term patient discomfort or 
even complaints. The choice to perform additional buckle 
surgery in the cases presented here was based on the extent 
of retinal traction/retinal shortening and the behavior of the 
retinal tissue when PFO was filled into the vitreous cavity. 
Whether or not the encircling buckle would have been neces-
sary in each of the cases to achieve stable reattachment (ie, 
using PFO alone) cannot be sufficiently answered. This is 
a shortcoming of this study and may only be identified in 
larger prospective series.
We have shown that a staged approach using PFO as a 
primary short-term endotamponade in a 23G PPV surgery 
approach allows for satisfactory management of complex 
RD with minimal complications and a comparable outcome 
compared with previous report in similar patients. The main 
advantages are the good predictability to reattach the retina, 
as well as the significantly reduced number of surgeries that 
are required to achieve retinal reattachment resulting in the 
long-term success rate as demonstrated by the long follow-up 
period in our study.
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